



US 20190248897A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2019/0248897 A1**
Ng et al. (43) **Pub. Date: Aug. 15, 2019**(54) **BISPECIFIC ASYMMETRIC
HETERODIMERS COMPRISING ANTI-CD3
CONSTRUCTS**(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)(72) Inventors: **Gordon Yiu Kon Ng**, Vancouver (CA);
Surjit Bhimarao Dixit, Richmond
(CA); **Thomas Spreter von**
Kruedenstein, Vancouver (CA); **Nina**
E. Weissner, Delta (CA)(21) Appl. No.: **16/256,824**(22) Filed: **Jan. 24, 2019****Related U.S. Application Data**(63) Continuation of application No. 13/941,449, filed on
Jul. 13, 2013.(60) Provisional application No. 61/845,948, filed on Jul.
12, 2013, provisional application No. 61/671,640,
filed on Jul. 13, 2012.**Publication Classification**(51) **Int. Cl.**
C07K 16/28 (2006.01)
C07K 16/32 (2006.01)(52) **U.S. Cl.**CPC **C07K 16/2809** (2013.01); **C07K 2317/52**
(2013.01); **C07K 16/32** (2013.01); **C07K**
16/2803 (2013.01); **C07K 2317/92** (2013.01);
C07K 2317/74 (2013.01); **C07K 2317/732**
(2013.01); **C07K 2317/73** (2013.01); **C07K**
2317/72 (2013.01); **C07K 2317/71** (2013.01);
C07K 2317/64 (2013.01); **C07K 2317/622**
(2013.01); **C07K 2317/528** (2013.01); **C07K**
2317/526 (2013.01); **C07K 2317/35** (2013.01);
C07K 2317/31 (2013.01); **C07K 2317/94**
(2013.01); **C07K 2319/31** (2013.01); **C07K**
2317/524 (2013.01); **C07K 16/2887** (2013.01)

(57)

ABSTRACT

Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

Specification includes a Sequence Listing.